Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
Recruiting
N/AInterventional Study
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
50 – 90
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
Baycrest · Other
Who this trial is looking for
This trial is looking for people with mild to moderate Alzheimer's Disease. Participants will receive a specific type of brain stimulation to see if it improves their ability to name things.
Are You a Good Fit for This Trial?
You may be able to join if
I have mild to moderate Alzheimer's Disease.
I scored between 18 and 25 on the MoCA.
I have completed the Cambridge Naming Task pre-assessment.
You may not be able to join if
I have a history of stroke or traumatic brain injury.
I have shunts or metal in my body.
I have a history of significant heart disease.
I have a history of alcoholism or drug use.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective t…
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Mild to Moderate AD
* Score between 18 and 25 on the MoCA
* Score on the Cambridge Naming Task during the pre-assessment
Exclusion Criteria:
* No history of stroke or TBI
* No shunts or metal in the body
* No history of significant heart disease, alcoholism and drug use
Inclusion Criteria:
* Mild to Moderate AD
* Score between 18 and 25 on the MoCA
* Score on the Cambridge Naming Task during the pre-assessment
Exclusion Criteria:
* No history of stroke or TBI
* No shunts or metal in the body
* No history of significant heart disease, alcoholism and drug use
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.